Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12582258 | 0.88 | ERN1 (0.54) | MAPTTRPM8ERN1HDAC3HDAC4 | |
| SCHEMBL4338533 | 0.87 | ERN1 (0.56) | IKBKBMAPTTRPM8ERN1HDAC3 | |
| SCHEMBL1784438 | 0.86 | ERN1 (0.56) | MAPTERN1HDAC3HDAC4HDAC1 | |
| SCHEMBL18832290 | 0.86 | PRF1 (0.54) | MAPTERN1HDAC3HDAC4HDAC1 | |
| SCHEMBL5204528 | 0.85 | PRF1 (0.56) | IKBKBMAPTTRPM8PRKCZESR1 | |
| SCHEMBL2715947 | 0.85 | KDM4E (0.59) | MAPTTRPM8ERN1HDAC3HDAC4 | |
| SCHEMBL2028546 | 0.85 | MAPT (0.62) | IKBKBMAPTERN1HDAC3HDAC4 | |
| SCHEMBL12470090 | 0.84 | ALDH1A1 (0.57) | MAPTTRPM8ERN1HDAC3HDAC4 | |
| SCHEMBL17201558 | 0.84 | ERN1 (0.49) | MAPTTRPM8ERN1HDAC3HDAC4 | |
| SCHEMBL6361017 | 0.84 | KDM4E (0.61) | MAPTERN1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2142554-B1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| CN-101481380-B | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MED XINCHANG PHARM | 2012-10-17 | — | — | CN | disclosed |
| US-7973159-B2 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110034375-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-7851622-B2 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-14 | — | — | US | disclosed |
| CN-101687882-A | Non-basic melanin concentrating hormone receptor body-1 antagonist | BRISTOL MYERS SQUIBB CO | 2010-03-31 | — | — | CN | disclosed |
| EP-2142554-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |
| WO-2008134480-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269110-A1 | 6-(4-Chlorophenyl)-3-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-thieno[3,2-d][1,2,3]triazin-4(3H)-one, for example; for treating a patient suffering from an MCHR-1 modulated disease or disorder such as obesity, diabetes, depression or anxiety | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034375-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | IKBKB 3353/4885MAPT 2294/4885TRPM8 1904/4885 |
| US-20080269110-A1 | 6-(4-Chlorophenyl)-3-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-thieno[3,2-d][1,2,3]triazin-4(3H)-one, for example; for treating a patient suffering from an MCHR-1 modulated disease or disorder such as obesity, diabetes, depression or anxiety | MCHR1, MCHR2, MC3R | IKBKB 3126/4885MAPT 2306/4885TRPM8 2344/4885 |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | CHEK2, CHEK1, PLK1 | IKBKB 704/4885MAPT 2544/4885TRPM8 3201/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | IKBKB 704/4885MAPT 2544/4885TRPM8 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.